Early Breast Cancer,KANJINTI is indicated for the treatment of HER2-positive early breast cancer following surgery, and in association with chemotherapy and, if applicable, radiotherapy.,Locally Advanced Breast Cancer,KANJINTI is indicated for the treatment of HER2-positive locally advanced breast cancer in combination with neoadjuvant chemotherapy followed by adjuvant KANJINTI.,Metastatic Breast Cancer,KANJINTI is indicated for the treatment of patients with metastatic breast cancer who have tumours that overexpress HER2:,a) as monotherapy for the treatment of those patients who have received one or more chemotherapy regimens for their metastatic disease;,b) in combination with taxanes for the treatment of those patients who have not received chemotherapy for their metastatic disease; or,c) in combination with an aromatase inhibitor for the treatment of post-menopausal patients with hormone-receptor positive metastatic breast cancer.,Advanced Gastric Cancer,KANJINTI is indicated in combination with cisplatin and either capecitabine or 5-FU for the treatment of patients with HER2 positive advanced adenocarcinoma of the stomach or gastro-oesophageal junction who have not received prior anti-cancer treatment for their metastatic disease.
How to take it
The way to take this medicine is: Intravenous Infusion.
Store at 2 to 8 degrees Celsius
Refrigerate
Do not Freeze
Protect from Light
Shelf lifetime is 36 Months.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Visual appearance
white to pale yellow lyophilised powder. Reconstituted solution colourless to slightly yellow liquid
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is
Schedule 4 : Prescription Only Medicine.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Early Breast Cancer,KANJINTI is indicated for the treatment of HER2-positive early breast cancer following surgery, and in association with chemotherapy and, if applicable, radiotherapy.,Locally Advanced Breast Cancer,KANJINTI is indicated for the treatment of HER2-positive locally advanced breast cancer in combination with neoadjuvant chemotherapy followed by adjuvant KANJINTI.,Metastatic Breast Cancer,KANJINTI is indicated for the treatment of patients with metastatic breast cancer who have tumours that overexpress HER2:,a) as monotherapy for the treatment of those patients who have received one or more chemotherapy regimens for their metastatic disease;,b) in combination with taxanes for the treatment of those patients who have not received chemotherapy for their metastatic disease; or,c) in combination with an aromatase inhibitor for the treatment of post-menopausal patients with hormone-receptor positive metastatic breast cancer.,Advanced Gastric Cancer,KANJINTI is indicated in combination with cisplatin and either capecitabine or 5-FU for the treatment of patients with HER2 positive advanced adenocarcinoma of the stomach or gastro-oesophageal junction who have not received prior anti-cancer treatment for their metastatic disease.
How to take it
The way to take this medicine is: Intravenous Infusion.
Store at 2 to 8 degrees Celsius
Refrigerate
Do not Freeze
Protect from Light
Shelf lifetime is 36 Months.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Visual appearance
white to pale yellow lyophilised powder. Reconstituted solution colourless to slightly yellow liquid
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is
Schedule 4 : Prescription Only Medicine.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Government Accredited with over 140 information partners
We are a government-funded service, providing quality, approved health information and advice
Healthdirect Australia acknowledges the Traditional Owners of Country throughout Australia and their continuing
connection to land, sea and community. We pay our respects to the Traditional Owners and to Elders both past and
present.